About Magellan Biosciences, Inc.

Company description – Magellan’s innovative technologies make diagnostic testing easier, more cost-effective, and less labor intensive. The company’s products deliver the timely information that clinicians need to make appropriate treatment decisions and improve outcomes for patients. Magellan has approximately 290 employees worldwide.

Growth strategy – Magellan’s three-pillar value-creation strategy includes:

• Improving productivity by sharing best practices and expertise across the company and through a lean, efficient operations platform
• Driving organic growth by accelerating investments in breakthrough development projects that build on Magellan’s track record of innovation and success in bringing products to market that make diagnostic testing easier, more cost-effective, and less labor-intensive
• Partnering with synergistic companies that share Magellan’s commitment to improving testing workflow for customers, and turbo-charging growth with a strong recurring revenue stream business model

Ownership and financial information – A privately held company, Magellan Biosciences is majority-owned by Ampersand Ventures. Other investors include Abingworth Management, Boston Community Venture Fund, Hambrecht & Quist Capital Management, KBL Healthcare Ventures, New England Partners Capital LP, and Nexus Medical Partners II SICAR. As such, we do not release our company financials. Our goal is to deliver double-digit revenue growth, balanced between internal growth and acquisitions.

Executive management team

Hiroshi Uchida – Magellan President and CEO

James Whelan – POC and Microbiology

Adrian Bunce – Immunoassay/Automated Solutions

Pam Gornall – Magellan CFO

Jeffrey M. Cohen – Vice President, Information Technologies

Debra Manning Dutko – Director of Human Resources

Board of directors

Herbert Hooper, PhD – Magellan Chairman, Managing General Partner of Ampersand Ventures (private equity investments)

Michael F. Bigham – Abingworth Management Director, responsible for the Boston office (venture capital firm)

Heiner Dreismann, PhD – Former President and CEO, Roche Molecular Diagnostics (PCR-based molecular diagnostic tests)

Peter H. Glick – Ampersand Ventures General Partner (private equity investments)

Laurence R. McCarthy, PhD – Former President and CEO of Focus Diagnostics, Inc., (developer of novel assays and diagnostic-testing services)

Daniel R. Omstead, Eng.ScD – President and CEO, Hambrecht & Quist Capital Management (registered investment advisor)

Hiroshi Uchida, PhD – Magellan President and CEO

Michael E. Woehler, PhD – President and CEO, Medifacts International (contract clinical-trial services to the pharmaceutical, biotech, and medical-device industries

Contact Us

Back to top